Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021)....

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 43; no. 6; pp. 779 - 782
Main Authors:	Ritchie, Marylyn D., Haas, David W., Motsinger, Alison A., Donahue, John P., Erdem, Huso, Raffanti, Stephen, Rebeiro, Peter, George, Alfred L., Kim, Richard B., Haines, Jonathan L., Sterling, Timothy R.
Format:	Journal Article
Language:	English
Published:	Chicago, IL The University of Chicago Press 15-09-2006 University of Chicago Press Oxford University Press
Subjects:	Adult Anti-HIV Agents - adverse effects Anti-HIV Agents - metabolism Anti-HIV Agents - therapeutic use Antiretroviral drugs Antiretrovirals Aryl Hydrocarbon Hydroxylases - genetics Benzoxazines Biological and medical sciences Biological variation Case-Control Studies Chemical and Drug Induced Liver Injury Cytochrome P-450 CYP2B6 Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System - genetics Dimensionality reduction Drug therapy Drug toxicity and drugs side effects treatment Exanthema Female Fever Genes Genes, MDR Genetic Variation Genotype Hepatitis Hepatitis antigens Hepatotoxicity HIV Infections - drug therapy HIV-1 HIV/AIDS Human genetics Humans Infectious diseases Liver - drug effects Liver Diseases - genetics Liver Diseases - virology Male Medical genetics Medical sciences Nevirapine - adverse effects Nevirapine - metabolism Nevirapine - therapeutic use Oxazines - adverse effects Oxazines - metabolism Oxazines - therapeutic use Oxidoreductases, N-Demethylating - genetics Pharmacology. Drug treatments Reverse transcriptase inhibitors Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - metabolism Reverse Transcriptase Inhibitors - therapeutic use Toxicity Toxicity: digestive system Infection Digestive diseases Hepatic disease Toxicity Hepatotoxicity Reverse transcriptase inhibitor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).
Bibliography:	istex:FD25681F3FA0B0B45F72CEA0DB50385CF8A00724 ark:/67375/HXZ-1VP0XZKD-7 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1058-4838 1537-6591
DOI:	10.1086/507101